This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DaVita Clinical Research Announces Scientific Collaboration With Dr. Jon Ruckle

DaVita Clinical Research ® (DCR ®), a specialty contract research organization with services spanning the full spectrum of drug and device development, announced today a non-exclusive agreement with Pacific Pharma Group, LLC, to provide consulting, program strategy and protocol design support for clinical pharmacology studies performed at DCR.

Jon Ruckle, M.D., CPI, principal at Pacific Pharma Group, will collaborate with DCR to continue to expand DCR’s Phase I research capabilities. Dr. Ruckle has served as investigator for more than 350 studies across multiple therapeutic areas including diabetes, cardiovascular disease, hypertension and osteoporosis, as well as first-in-human trials with biologics and small molecules.

“We are excited to enter into this consulting relationship with Pacific Pharma Group and to extend our scientific team to include the experience of Dr. Ruckle,” said Chad Jaeger, vice president of early clinical research at DCR. “Our intense focus on patient safety and scientific integrity in complex clinical pharmacology services aligns well with this collaboration and the needs of our customers.”

In addition to serving as principal at Pacific Pharma Group, Dr. Ruckle is currently assistant clinical professor at the John A. Burns School of Medicine at the University of Hawaii in Honolulu. Previously, he held medical director positions at Comprehensive Clinical Development, Inc., Covance Clinical Research Unit and Radiant Research Unit Honolulu. He was medical director and co-founder of Northwest Kinetics, Inc., and has authored more than 30 medical publications.

“State-of-the-art, hospital-based Phase I facilities offering access to both patient and healthy normal populations are of great interest to pharmaceutical researchers,” said Dr. Ruckle. “Through our relationship with DCR, Pacific Pharma Group will be able to offer clients access to these valuable services.”

Dr. Ruckle completed his medical degree at the Loma Linda University Medical School in Loma Linda, Calif., and his internal medicine residency training at the Mayo Clinic in Rochester, Minn. Dr. Ruckle is board certified in Internal Medicine and is a Certified Physician Investigator through the Academy of Pharmaceutical Physicians and Investigators.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs